<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Neurosurgery Blog &#187; Pituitary</title>
	<atom:link href="http://www.neurosurgery-blog.com/archives/category/pituitary/feed" rel="self" type="application/rss+xml" />
	<link>http://www.neurosurgery-blog.com</link>
	<description>Daily bibliographic and video review of the Neurosurgery Department. La Fe University Hospital. Valencia, Spain</description>
	<lastBuildDate>Thu, 09 Feb 2012 23:00:45 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Transsphenoidal Surgery for Cushing Disease: Experience With 136 Patients</title>
		<link>http://www.neurosurgery-blog.com/archives/3641</link>
		<comments>http://www.neurosurgery-blog.com/archives/3641#comments</comments>
		<pubDate>Sun, 08 Jan 2012 23:00:49 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[Cushing disease]]></category>
		<category><![CDATA[Immediate postoperative remission]]></category>
		<category><![CDATA[Long-term results]]></category>
		<category><![CDATA[Statistical analysis]]></category>
		<category><![CDATA[Transsphenoidal surgery]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3641</guid>
		<description><![CDATA[Neurosurgery 70:70–81, 2012 DOI: 10.1227/NEU.0b013e31822dda2c
This is a retrospective study of 136 patients with Cushing disease treated with transsphenoidal microsurgery.
OBJECTIVE: To evaluate factors influencing immediate postoperative results and longterm outcomes.
METHODS: Data regarding clinical presentation, endocrine evaluation, imaging studies, surgical technique, immediate postoperative biochemical remission (IPBR), and longterm results were entered into a database and analyzed statistically. [...]]]></description>
			<content:encoded><![CDATA[<p style="text-align: justify;"><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/Transsphenoidal_Surgery_for_Cushing_Disease__.jpg"><img class="alignleft size-thumbnail wp-image-3642" title="Transsphenoidal_Surgery_for_Cushing_Disease__" src="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/Transsphenoidal_Surgery_for_Cushing_Disease__-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 70:70–81, 2012 DOI: 10.1227/NEU.0b013e31822dda2c</strong></p>
<p style="text-align: justify;">This is a retrospective study of 136 patients with Cushing disease treated with transsphenoidal microsurgery.</p>
<p style="text-align: justify;">OBJECTIVE: To evaluate factors influencing immediate postoperative results and longterm outcomes.</p>
<p style="text-align: justify;">METHODS: Data regarding clinical presentation, endocrine evaluation, imaging studies, surgical technique, immediate postoperative biochemical remission (IPBR), and longterm results were entered into a database and analyzed statistically. IPBR was based on biochemical evidence of adrenal cortical insufficiency and clinical evidence of such insufficiency.</p>
<p style="text-align: justify;">RESULTS: IPBR for the entire series was 83.4%. In microadenomas, IPBR was 89.8% with a mean immediate postoperative plasma cortisol (IPPC) of 2.1 mg/dL (range, ,0.5-5.3). Positive magnetic resonance imaging (MRI) was associated with 18 times greater odds of finding microadenoma at surgery (P &lt; .001) and with 4.1 times greater odds of IPBR (P = .07). In patients with a negative MRI, a positive inferior petrosal sinus sampling (IPSS) test was associated with 93% of IPBR (P = .004). IPBR in macroadenomas was 30.7%. Of patients followed for 12 months or longer, 34.8% required glucocorticoid replacement for the duration of follow-up. The mean follow-up in microadenomas was 68.4 months with a 9.67% incidence of recurrences. The estimated actuarial incidence of recurrences increased with the passage of time and IPPC of greater than 2 mg/dL was associated with higher incidence of recurrences, although without statistical significance (P = .08).</p>
<p style="text-align: justify;">CONCLUSION: In microadenomas, a positive MRI and positive IPSS test were associated with a higher incidence of IPBR. Recurrences increased with the passage of time, and an IPPC of greater than 2 mg/dL may be associated with higher incidence of recurrences.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3641/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Endoscopic, Endonasal Resection of Craniopharyngiomas: Analysis of Outcome Including Extent of Resection, Cerebrospinal Fluid Leak, Return to Preoperative Productivity, and Body Mass Index</title>
		<link>http://www.neurosurgery-blog.com/archives/3610</link>
		<comments>http://www.neurosurgery-blog.com/archives/3610#comments</comments>
		<pubDate>Sun, 01 Jan 2012 23:00:45 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Endoscopy]]></category>
		<category><![CDATA[Outcome]]></category>
		<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[craniopharyngioma]]></category>
		<category><![CDATA[Endonasal]]></category>
		<category><![CDATA[Endoscopic]]></category>
		<category><![CDATA[Intraventricular]]></category>
		<category><![CDATA[Minimal access]]></category>
		<category><![CDATA[Outcome measures]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3610</guid>
		<description><![CDATA[Neurosurgery 70:110–124, 2012 DOI: 10.1227/NEU.0b013e31822e8ffc
The endoscopic, endonasal, extended transsphenoidal approach is a minimal-access technique for managing craniopharyngiomas. Outcome measures such as return to employment and body mass index (BMI) have not been reported and are necessary for comparison with open transcranial approaches. Most prior reports of the endoscopic, endonasal approach have reported unacceptably high cerebrospinal [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/Endoscopic_Endonasal_Resection_of.jpg"><img class="alignleft size-thumbnail wp-image-3615" title="Endoscopic,_Endonasal_Resection_of" src="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/Endoscopic_Endonasal_Resection_of-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 70:110–124, 2012 DOI: 10.1227/NEU.0b013e31822e8ffc</strong></p>
<p style="text-align: justify;">The endoscopic, endonasal, extended transsphenoidal approach is a minimal-access technique for managing craniopharyngiomas. Outcome measures such as return to employment and body mass index (BMI) have not been reported and are necessary for comparison with open transcranial approaches. Most prior reports of the endoscopic, endonasal approach have reported unacceptably high cerebrospinal fluid (CSF) leak rates.</p>
<p style="text-align: justify;">OBJECTIVE: To assess the outcome of endoscopic, endonasal surgery in a consecutive series of craniopharyngiomas with special attention to extent of resection, CSF leak, return to employment, and BMI.</p>
<p style="text-align: justify;">METHODS: Twenty-six surgeries were performed on 24 patients at Weill Cornell Medical College-New York Presbyterian Hospital. Five patients had recurrent lesions. Gross-total resection (GTR) was attempted in 21 surgeries. Indications for intended subtotal resection were advanced age, medical comorbidities, preservation of pituitary function, and hypothalamic invasion.</p>
<p style="text-align: justify;">RESULTS: Mean tumor diameter was 2.9 cm. GTR (18 surgeries) or near-total (.95%) resection (2 surgeries) was achieved in 95% when GTR was the goal. Seven patients received postoperative radiation therapy. Mean follow-up was 35 months with no recurrences in GTR cases and stable disease in all patients at last follow-up. Vision improved in 77%. Diabetes insipidus and panhypopituitarism developed in 42% and 38%, respectively. A more than 9% increase in BMI occurred in 39%; 69% returned to their preoperative profession/schooling. The postoperative CSF leak rate was 3.8%.</p>
<p style="text-align: justify;">CONCLUSION: Minimal-access, endoscopic, endonasal surgery for craniopharyngioma can achieve high rates of GTR with low rates of CSF leak. Return to employment and obesity rates are comparable to microscope-assisted transcranial and transsphenoidal reports.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3610/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Suprasellar Rathke Cleft Cysts: Clinical Presentation and Treatment Outcomes</title>
		<link>http://www.neurosurgery-blog.com/archives/3371</link>
		<comments>http://www.neurosurgery-blog.com/archives/3371#comments</comments>
		<pubDate>Tue, 08 Nov 2011 23:00:53 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Outcome]]></category>
		<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[Rathke cleft cyst]]></category>
		<category><![CDATA[Suprasellar]]></category>
		<category><![CDATA[Transsphenoidal surgery]]></category>
		<category><![CDATA[Visual symptoms]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3371</guid>
		<description><![CDATA[Neurosurgery 69:1058–1069, 2011 DOI: 10.1227/NEU.0b013e318228bcea
Rathke cleft cysts (RCCs), benign remnants of the Rathke pouch typically arising in the sella, sometimes have suprasellar extension. Purely suprasellar RCCs are rarely reported.
OBJECTIVE: To compare the presentations, surgical outcomes, and pathology of purely suprasellar RCCs and sellar-based RCCs.
METHODS: We retrospectively reviewed records, magnetic resonance images, laboratory results, and pathology [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/Suprasellar_Rathke_Cleft_Cysts___Clinical.jpg"><img class="alignleft size-thumbnail wp-image-3372" title="Suprasellar_Rathke_Cleft_Cysts___Clinical" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/Suprasellar_Rathke_Cleft_Cysts___Clinical-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 69:1058–1069, 2011 DOI: 10.1227/NEU.0b013e318228bcea</strong></p>
<p style="text-align: justify;">Rathke cleft cysts (RCCs), benign remnants of the Rathke pouch typically arising in the sella, sometimes have suprasellar extension. Purely suprasellar RCCs are rarely reported.</p>
<p style="text-align: justify;">OBJECTIVE: To compare the presentations, surgical outcomes, and pathology of purely suprasellar RCCs and sellar-based RCCs.</p>
<p style="text-align: justify;">METHODS: We retrospectively reviewed records, magnetic resonance images, laboratory results, and pathology of 151 RCC patients surgically managed at our institution from 1989 to 2009. The RCCs were classified as purely sellar (type I, n = 76), sellar with suprasellar extension (type II, n = 56), or purely suprasellar (type III, n = 19).</p>
<p style="text-align: justify;">RESULTS: The RCCs with a suprasellar component (types II and III) more commonly presented with visual dysfunction (P &lt; .001). Complete cyst drainage occurred in 89%, 55%, and 38% of type I, II, and III RCCs, respectively (P &lt; .001). Vision improved in 100%, 55%, and 33% and headache improved in 74%, 64%, and 29% of type I, II, and III patients, respectively (P = .02). Temporary or permanent postoperative diabetes insipidus occurred in 5%, 16%, and 21% of type I, II, and III patients, respectively. (P &lt; .001). In a multivariate analysis, RCC type was the only factor predicting recurrence. Kaplan-Meier 3-year recurrence/progression rates were 0%, 16%, and 29% for type I, II, and III RCCs, respectively (P , .001, type I vs II, type I vs III; P = .5 type II vs III).</p>
<p style="text-align: justify;">CONCLUSION: The RCCs with a suprasellar component are neurosurgically challenging because of their proximity to the optic chiasm and infundibulum. Compared with sellar-based RCCs, RCCs with a suprasellar component more frequently present with visual dysfunction, are more difficult to completely eliminate, recur more frequently, and are associated with higher postoperative endocrine morbidity, and their preoperative visual dysfunction and headache less frequently improve with surgery. These factors must be considered during the treatment of RCCs with a suprasellar component.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Long-term Outcomes After Gamma Knife Radiosurgery for Patients With a Nonfunctioning Pituitary Adenoma</title>
		<link>http://www.neurosurgery-blog.com/archives/3087</link>
		<comments>http://www.neurosurgery-blog.com/archives/3087#comments</comments>
		<pubDate>Mon, 29 Aug 2011 22:00:36 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[gamma-knife]]></category>
		<category><![CDATA[hypopituitarism]]></category>
		<category><![CDATA[pituitary adenoma]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3087</guid>
		<description><![CDATA[Neurosurgery 69:284–293, 2011 DOI: 10.1227/NEU.0b013e31821bc44e
Nonfunctioning pituitary adenomas recur after microsurgery. Gamma Knife radiosurgery (GKRS) has been used to treat recurrent adenomas.
OBJECTIVE: To evaluate the long-term rates of tumor control and development of hypopituitarism in patients with nonfunctioning pituitary adenomas after GKRS.
METHODS: Forty-eight patients with a nonfunctioning pituitary adenoma treated between 1991 and 2004 at the [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/08/Long_term_Outcomes_After_Gamma_Knife_Radiosurgery.jpg"><img class="alignleft size-thumbnail wp-image-3090" title="Long_term_Outcomes_After_Gamma_Knife_Radiosurgery" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/08/Long_term_Outcomes_After_Gamma_Knife_Radiosurgery-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 69:284–293, 2011 DOI: 10.1227/NEU.0b013e31821bc44e</strong></p>
<p style="text-align: justify;">Nonfunctioning pituitary adenomas recur after microsurgery. Gamma Knife radiosurgery (GKRS) has been used to treat recurrent adenomas.</p>
<p style="text-align: justify;">OBJECTIVE: To evaluate the long-term rates of tumor control and development of hypopituitarism in patients with nonfunctioning pituitary adenomas after GKRS.</p>
<p style="text-align: justify;">METHODS: Forty-eight patients with a nonfunctioning pituitary adenoma treated between 1991 and 2004 at the University of Virginia were studied. All patients had more than 4 years of clinical and imaging follow-up.</p>
<p style="text-align: justify;">RESULTS: All patients underwent follow-up imaging and endocrine evaluations, with a duration ranging from 50 to 215 months (median, 80.5 months) and 57 to 201 months (median, 95 months), respectively. New hormone deficiency after GKRS occurred in 19 of 48 patients (39%). Corticotropin/cortisol deficiency developed in 8% of patients, thyroid hormone deficiency in 20.8%, gonadotropin deficiency in 4.2%, growth hormone/insulin-like growth factor 1 in 16.7%, and diabetes insipidus in 2%. Panhypopituitarism including diabetes insipidus developed in 1 patient. Overall, control of tumor volume was 83%. Tumor volume decreased in 36 patients (75%), increased in 8 patients (17%), and was unchanged in 4 patients (8%). Tumor volumes greater than 5 mL at the time of GKRS were associated with a significantly greater rate of growth (P = .003) compared with an adenoma with a volume of 5 mL or less.</p>
<p style="text-align: justify;">CONCLUSION: GKRS resulted in a high and durable rate of tumor control in patients with a nonfunctioning pituitary adenoma. A higher preoperative tumor volume was associated with an increased rate of tumor growth.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3087/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rathke cleft cysts: a review of clinical and surgical management</title>
		<link>http://www.neurosurgery-blog.com/archives/2840</link>
		<comments>http://www.neurosurgery-blog.com/archives/2840#comments</comments>
		<pubDate>Sun, 03 Jul 2011 22:00:50 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Clinical Guide]]></category>
		<category><![CDATA[Developmental Malformations]]></category>
		<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[craniopharyngioma]]></category>
		<category><![CDATA[Endoscopy]]></category>
		<category><![CDATA[pituitary adenoma]]></category>
		<category><![CDATA[Rathke cleft cyst]]></category>
		<category><![CDATA[transsphenoidal approach]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/archives/2840</guid>
		<description><![CDATA[Neurosurg Focus 31 (1):E1, 2011. DOI: 10.3171/2011.5.FOCUS1183
The aim of this paper is to provide a comprehensive review of clinical, imaging, and histopathological features, as well as operative and nonoperative management strategies in patients with Rathke cleft cysts (RCCs).
A literature review was performed to identify previous articles that reported surgical and nonsurgical management of RCCs.
Rathke cleft [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/07/Rathke-cyst.jpg"><img class="alignleft size-thumbnail wp-image-2841" title="Rathke cyst" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/07/Rathke-cyst-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurg Focus 31 (1):E1, 2011. DOI: 10.3171/2011.5.FOCUS1183</strong></p>
<p style="text-align: justify;">The aim of this paper is to provide a comprehensive review of clinical, imaging, and histopathological features, as well as operative and nonoperative management strategies in patients with Rathke cleft cysts (RCCs).</p>
<p style="text-align: justify;">A literature review was performed to identify previous articles that reported surgical and nonsurgical management of RCCs.</p>
<p style="text-align: justify;">Rathke cleft cysts are often incidental lesions found in the sellar and suprasellar regions and do not require surgical intervention in the majority of cases. In symptomatic RCCs, the typical clinical presentation includes headache, visual loss, and/or endocrine dysfunction. Visual field testing and endocrine laboratory studies may reveal more subtle deficiencies associated with RCCs. When indicated, the transsphenoidal approach typically offers the least invasive and safest method for treating these lesions.</p>
<p style="text-align: justify;">Various surgical strategies including cyst wall resection, intralesional alcohol injection, and sellar floor reconstruction are discussed. Although headache and visual symptoms frequently improve after surgical drainage of RCCs, hypopituitarism and diabetes insipidus are less likely to do so.</p>
<p style="text-align: justify;">A subset of more aggressive, atypical RCCs associated with pronounced clinical symptoms and higher recurrence rates is discussed, as well as the possible relationship of these lesions to craniopharyngiomas.</p>
<p style="text-align: justify;">Rathke cleft cysts are typically benign, asymptomatic lesions that can be monitored. In selected patients, transsphenoidal surgery provides excellent rates of improvement in clinical symptoms and long-term cyst resolution. Complete cyst wall resection, intraoperative alcohol cauterization, and sellar floor reconstruction in the absence of a CSF leak are not routinely recommended.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2840/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Microscopic endonasal transsphenoidal pituitary adenomectomy in the pediatric population</title>
		<link>http://www.neurosurgery-blog.com/archives/2668</link>
		<comments>http://www.neurosurgery-blog.com/archives/2668#comments</comments>
		<pubDate>Mon, 23 May 2011 22:00:59 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Endoscopy]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[endonasal transsphenoidal approach]]></category>
		<category><![CDATA[microscope]]></category>
		<category><![CDATA[pediatric adenoma]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2668</guid>
		<description><![CDATA[J Neurosurg Pediatrics 7:000–000, 2011.DOI: 10.3171/2011.2.PEDS10278
Pituitary adenomas are uncommon in childhood. Although medical treatment can be effective in treating prolactinomas and some growth hormone (GH)–secreting tumors, resection is indicated when visual function is affected or the side effects of medical therapy are intolerable. The authors of this report describe their 10-year experience in managing pituitary [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/05/pitapoplexy.jpg"><img class="alignleft size-thumbnail wp-image-2669" title="pitapoplexy" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/05/pitapoplexy-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg Pediatrics 7:000–000, 2011.DOI: 10.3171/2011.2.PEDS10278</strong></p>
<p style="text-align: justify;">Pituitary adenomas are uncommon in childhood. Although medical treatment can be effective in treating prolactinomas and some growth hormone (GH)–secreting tumors, resection is indicated when visual function is affected or the side effects of medical therapy are intolerable. The authors of this report describe their 10-year experience in managing pituitary adenomas via the microscopic endonasal transsphenoidal approach in a pediatric population.</p>
<p style="text-align: justify;">Methods. They performed a retrospective review of a surgical case series based at a single institution and consisting of 34 consecutive pediatric patients with endocrine-active (32 patients) and endocrine-inactive (2 patients) adenomas. These patients were surgically treated via an endonasal transsphenoidal approach between 1999 and 2008. Patient charts were reviewed, and clinical data were compiled and analyzed using the chi-square and Kaplan-Meier tests.</p>
<p style="text-align: justify;">Results. The patient cohort consisted of 20 girls and 14 boys, with ages ranging from 9 to 18 years and a median age of 16 years. Thirty-two patients (94%) underwent surgery for endocrine-active tumors, including 10 (29%) with Cushing disease, 21 (62%) with prolactinomas, and 1 (3%) with GH-secreting tumors. Two patients with nonsecreting adenomas underwent surgery for apoplexy. The mean tumor volume was 5.4 cm3, and 13 patients (38%) had suprasellar extension and 7 (21%) had cavernous sinus invasion. Gross-total resection was achieved in 26 patients (76%), although it was significantly less likely to be achieved in the setting of cavernous sinus invasion (p &lt; 0.001) but was unaffected by suprasellar extension. Residual tumor was treated with radiation therapy in 6 patients (18%). The average duration of hospital stay was 1.6 days. The median follow-up time was 18 months. After surgery, 19 patients (56%) had normal hormone function without adjuvant therapy, 8 (24%) had normal function with adjuvant therapy, and 5 (15%) had persistently elevated hormone levels. Patients with a macroprolactinoma were significantly more likely to require postoperative adjuvant therapy than were those with a microprolactinoma (p &lt; 0.03).</p>
<p style="text-align: justify;">Conclusions. Endonasal transsphenoidal resection is a safe, well-tolerated, and potentially curative treatment option for pituitary adenomas in children. Despite the technical challenges associated with this approach in the pediatric population, these tumors can be effectively managed with minimal morbidity. Endocrine function is usually preserved, and the majority of patients will not require lifelong medical therapy.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2668/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Transsphenoidal pseudocapsule-based extracapsular resection for pituitary adenomas</title>
		<link>http://www.neurosurgery-blog.com/archives/2536</link>
		<comments>http://www.neurosurgery-blog.com/archives/2536#comments</comments>
		<pubDate>Mon, 25 Apr 2011 04:00:15 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Endoscopy]]></category>
		<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[Surgical technique]]></category>
		<category><![CDATA[Extracapsular resection]]></category>
		<category><![CDATA[pituitary adenoma]]></category>
		<category><![CDATA[transsphenoidal approach]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2536</guid>
		<description><![CDATA[Acta Neurochir (2011) 153:799–806. DOI 10.1007/s00701-011-0961-1
In the past several years, increasing attention has been paid to the utility of a pseudocapsule in transphenoidal surgery for pituitary adenomas. However, prior studies focused more on the histological structure of the pseudocapsule and surgical technique. The objective of this study was to evaluate the overall therapeutic effectiveness of [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/04/transsphenoidal-extracapsular-app.png"><img class="alignleft size-thumbnail wp-image-2538" title="transsphenoidal extracapsular app" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/04/transsphenoidal-extracapsular-app-150x150.png" alt="" width="150" height="150" /></a>Acta Neurochir (2011) 153:799–806. DOI 10.1007/s00701-011-0961-1</strong></p>
<p style="text-align: justify;">In the past several years, increasing attention has been paid to the utility of a pseudocapsule in transphenoidal surgery for pituitary adenomas. However, prior studies focused more on the histological structure of the pseudocapsule and surgical technique. The objective of this study was to evaluate the overall therapeutic effectiveness of transsphenoidal pseudocapsule-based extracapsular resection for pituitary adenomas.</p>
<p style="text-align: justify;">Methods Between January 2004 and October 2007, 78 patients with pituitary adenomas underwent transsphenoidal pseudocapsule-based extracapsular removal surgery (extracapsular resection group, ER group). During the same period, 64 patients underwent transsphenoidal intracapsular resection operations (intracapsular resection group, IR group).</p>
<p style="text-align: justify;">Results Complete resection rates were achieved in 90.6%, 84.6% and 65.5%, 52.6% of modified Hardy types II and III in the ER and IR groups, showing a significant difference (both P&lt;0.05). Statistical significance in the remission rates was also found between the two groups with modified Hardy types II and III, respectively (both P&lt;0.05). Complications occurred in 29.5% of the ER group and 26.6% of the IR group, with no difference between groups (P&gt;0.05). The recurrence rate of the ER group (2.56%) was lower than that of the IR group (14.06%).</p>
<p style="text-align: justify;">Conclusion The transsphenoidal pseudocapsule-based extracapsular resection approach provides a more effective and safe alternative compared to the traditional intracapsular one because of its higher tumor removal and remission rates, and lower recurrence rate.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2536/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Atypical pituitary adenomas: incidence, clinical characteristics, and implications</title>
		<link>http://www.neurosurgery-blog.com/archives/2217</link>
		<comments>http://www.neurosurgery-blog.com/archives/2217#comments</comments>
		<pubDate>Wed, 16 Feb 2011 05:00:08 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[atypical]]></category>
		<category><![CDATA[carcinoma]]></category>
		<category><![CDATA[Ki 67]]></category>
		<category><![CDATA[MIB-1]]></category>
		<category><![CDATA[p53]]></category>
		<category><![CDATA[pituitary adenoma]]></category>
		<category><![CDATA[transsphenoidal]]></category>
		<category><![CDATA[tumor biology]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2217</guid>
		<description><![CDATA[J Neurosurg 114:336–344, 2011.DOI: 10.3171/2010.8.JNS10290
The 2004 WHO classification of pituitary adenomas now includes an “atypical” variant, defined as follows: MIB-1 proliferative index greater than 3%, excessive p53 immunoreactivity, and increased mitotic activity. The authors review the incidence of this atypical histopathological subtype and its correlation with tumor subtype, invasion, and surgical features.
Methods. The records of [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/02/atypicaladenoma.jpg"><img class="alignleft size-thumbnail wp-image-2221" title="atypicaladenoma" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/02/atypicaladenoma-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 114:336–344, 2011.DOI: 10.3171/2010.8.JNS10290</strong></p>
<p style="text-align: justify;">The 2004 WHO classification of pituitary adenomas now includes an “atypical” variant, defined as follows: MIB-1 proliferative index greater than 3%, excessive p53 immunoreactivity, and increased mitotic activity. The authors review the incidence of this atypical histopathological subtype and its correlation with tumor subtype, invasion, and surgical features.</p>
<p style="text-align: justify;">Methods. The records of 121 consecutive patients who underwent transsphenoidal surgery for pituitary adenomas during an 18-month period were retrospectively reviewed for evidence of atypical adenomas.</p>
<p style="text-align: justify;">Results. Eighteen adenomas (15%) met the criteria for atypical lesions; 17 (94%) of the 18 were macroadenomas. On imaging, 15 (83%) demonstrated imaging evidence of surrounding invasion, compared with 45% of typical adenomas (p = 0.004). Atypical tumors occurred in 12 female (67%) and 6 male (33%) patients. Patient age ranged from 16 to 70 years (mean 48 years). Nine patients (50%) had hormonally active tumors, and 9 had nonfunctional lesions. Four (22%) of the 18 patients presented to us with recurrent tumors. Immunohistochemical analysis demonstrated the following tumor subtypes: GH-secreting adenoma with plurihormonal staining (5 patients [28%]); null-cell adenoma (5 patients [28%]); silent ACTH tumor (3 patients [17%]), ACTH-staining tumor with Cushing’s disease (2 patients [11%]), prolactinoma (2 patients [11%]), and silent FSH-staining tumor (1 patient [6%]). The MIB-1 labeling index ranged from 3% to 20% (mean 7%).</p>
<p style="text-align: justify;">Conclusions. Atypical tumors were identified in 15% of resected pituitary adenomas, and they tended to be aggressive, invasive macroadenomas. More longitudinal follow-up is required to determine whether surgical outcomes, potential for recurrence, or metastasis of atypical adenomas vary significantly from their typical counterparts.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2217/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Intraoperative computed tomography registration and electromagnetic neuronavigation for transsphenoidal pituitary surgery: accuracy and time effectiveness</title>
		<link>http://www.neurosurgery-blog.com/archives/2160</link>
		<comments>http://www.neurosurgery-blog.com/archives/2160#comments</comments>
		<pubDate>Thu, 03 Feb 2011 05:00:57 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[Surgical technique]]></category>
		<category><![CDATA[electromagnetic navigation]]></category>
		<category><![CDATA[Intraoperative computed tomography]]></category>
		<category><![CDATA[Pituitary tumor]]></category>
		<category><![CDATA[stereotactic navigation]]></category>
		<category><![CDATA[time effectiveness]]></category>
		<category><![CDATA[transsphenoidal approach]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2160</guid>
		<description><![CDATA[J Neurosurg 114:329–335, 2011. (DOI: 10.3171/2010.5.JNS091821)
The authors assessed the feasibility, anatomical accuracy, and cost effectiveness of frameless electromagnetic (EM) neuronavigation in conjunction with portable intraoperative CT (iCT) registration for transsphenoidal adenomectomy (TSA).
Methods. A prospective database was established for data obtained in 208 consecutive patients who underwent TSA in which the iCT/EM navigation technique was used. [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/02/EMnavig.jpg"><img class="alignleft size-thumbnail wp-image-2161" title="EMnavig" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/02/EMnavig-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 114:329–335, 2011. (DOI: 10.3171/2010.5.JNS091821)</strong></p>
<p style="text-align: justify;">The authors assessed the feasibility, anatomical accuracy, and cost effectiveness of frameless electromagnetic (EM) neuronavigation in conjunction with portable intraoperative CT (iCT) registration for transsphenoidal adenomectomy (TSA).</p>
<p style="text-align: justify;">Methods. A prospective database was established for data obtained in 208 consecutive patients who underwent TSA in which the iCT/EM navigation technique was used. Data were compared with those acquired in a retrospective cohort of 65 consecutive patients in whom fluoroscope-assisted TSA had been performed by the same surgeon. All patients in both groups underwent transnasal removal of pituitary adenomas or neuroepithelial cysts, using identical surgical techniques with an operating microscope. In the iCT/EM technique–treated cases, a portable iCT scan was obtained immediately prior to surgery for registration to the EM navigation system, which did not require rigid head fixation. Preexisting (nonnavigation protocol) MR imaging studies were fused with the iCT scans to enable 3D navigation based on MR imaging data. The accuracy of the navigation system was determined in the first 50 iCT/EM cases by visual concordance of the navigation probe location to 5 preselected bony landmarks. For all patients in both cohorts, total operating room time, incision-to-closure time, and relative costs of imaging and surgical procedures were determined from hospital records.</p>
<p style="text-align: justify;">Results. In every case, iCT registration was successful and preoperative MR images were fused to iCT scans without affecting navigation accuracy. There was 100% concordance between probe tip location and predetermined bony loci in the first 50 cases involving the iCT/EM technique. Total operating room time was significantly less in the iCT/EM cases (mean 108.9 ± 24.3 minutes [208 patients]) compared with the fluoroscopy group (mean 121.1 ± 30.7 minutes [65 patients]; p &lt; 0.001). Similarly, incision-to-closure time was significantly less for the iCT/EM cases (mean 61.3 ± 18.2 minutes) than for the fluoroscopy cases (mean 71.75 ± 19.0 minutes; p &lt; 0.001). Relative overall costs for iCT/EM technique and intraoperative C-arm fluoroscopy were comparable; increased costs for navigation equipment were offset by savings in operating room costs for shorter procedures.</p>
<p style="text-align: justify;">Conclusions. The use of iCT/MR imaging–guided neuronavigation for transsphenoidal surgery is a time-effective, cost-efficient, safe, and technically beneficial technique.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Repeat Transsphenoidal Surgery for the Treatment of Remaining or Recurring Pituitary Tumors in Acromegaly</title>
		<link>http://www.neurosurgery-blog.com/archives/1748</link>
		<comments>http://www.neurosurgery-blog.com/archives/1748#comments</comments>
		<pubDate>Fri, 29 Oct 2010 04:00:44 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[acromegaly]]></category>
		<category><![CDATA[Cavernous sinus invasion]]></category>
		<category><![CDATA[Long-term outcome]]></category>
		<category><![CDATA[Recurrence]]></category>
		<category><![CDATA[Repeat transsphenoidal surgery]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=1748</guid>
		<description><![CDATA[Neurosurgery 67:949–956, 2010 DOI: 10.1227/NEU.0b013e3181ec4379
Acromegaly is a disorder characterized by hypersecretion of growth hormone caused by a growth hormone–secreting pituitary adenoma.
OBJECTIVE: To evaluate the long-term efficacy and safety of repeat transsphenoidal surgery for persistent or recurrent acromegaly.
METHODS: We retrospectively reviewed records for 53 acromegalic patients who underwent repeat transsphenoidal surgery for persistent or progressive acromegaly [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2010/10/acromegaly.jpg"><img class="alignleft size-thumbnail wp-image-1752" title="acromegaly" src="http://www.neurosurgery-blog.com/wp-content/uploads/2010/10/acromegaly-150x150.jpg" alt="" width="120" height="120" /></a>Neurosurgery 67:949–956, 2010 DOI: 10.1227/NEU.0b013e3181ec4379</strong></p>
<p style="text-align: justify;">Acromegaly is a disorder characterized by hypersecretion of growth hormone caused by a growth hormone–secreting pituitary adenoma.</p>
<p style="text-align: justify;">OBJECTIVE: To evaluate the long-term efficacy and safety of repeat transsphenoidal surgery for persistent or recurrent acromegaly.</p>
<p style="text-align: justify;">METHODS: We retrospectively reviewed records for 53 acromegalic patients who underwent repeat transsphenoidal surgery for persistent or progressive acromegaly at Toranomon Hospital between 1987 and 2006. Multivariate logistic regression was performed to evaluate preoperative factors influencing the surgical outcome.</p>
<p style="text-align: justify;">RESULTS: Thirty-one patients (58.5%) met the criteria for cure on long-term follow-up endocrine findings. Furthermore, 17 patients were well controlled with normal insulinlike growth factor I levels without (2 patients) or with medication (15 patients), whereas insulin-like growth factor I levels were still above normal in 5 patients after postoperative adjuvant therapy. Only 1 patient was undergoing additional hormonal replacement after surgery, although transient cerebrospinal fluid leak, transient abducens nerve palsy, severe nasal bleeding, and pituitary abscess occurred in each patient, respectively. Multivariate analysis clarified that a favorable surgical outcome was achieved in patients without cavernous sinus invasion (hazard ratio 12.56), tumor segmentation (hazard ratio 5.82), or in those older than 40 years old (hazard ratio 3.21).</p>
<p style="text-align: justify;">CONCLUSION: Repeat surgery can be performed safely with an approximately 60% long-term cure rate in this series. Reoperation should therefore be considered for persistent or recurrent disease in acromegalic patients in whom adjuvant therapy is not effective enough or cannot be accepted. The careful study of initial or preoperative magnetic resonance imaging and the use of micro-Doppler, endoscope, and eye movement monitoring device during surgery can help increase cure rate with a lower complication rate.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/1748/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

